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Introduction
In recent years, a new phenomenon has emerged in 
the context of the field “tobacco smoking”: the electronic 
cigarette, a device very similar to the traditional cigarette 
but without the burning of tobacco.
The e-cigarette, also known as e-cigarette or e-cig, is 
an integrated electric device, including a wide range of 
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products defined as personal vaporizers, advanced personal 
vaporizers or electronic nicotine delivery systems. These 
devices have different designs even if, usually, they are 
made with very similar appearance to traditional cigarette. 
E-cig are generally constituted by a stainless steel shell, a 
lithium ion battery assembly, a smart chip with program 
controlled circuits, and an atomization chamber. Besides 
e-cig presents a removable cartridge containing flavouring, 
a mixture of propylene glycol and other products obtained 
from an extraction of tobacco flavours and, in some cases, 
other aromas to the mixture such as: mint, strawberry, orange 
etc. Also, some removable cartridges contain nicotine at 
different concentrations together with flavor (1, 2).
The possibility to inhale nicotine as an alternative to 
tobacco smoke is one of the most important reasons of the 
popularity of e-cig: smokers may continue to “smoke” and 
inhale nicotine (the most responsible of tobacco dependence) 
avoiding to inhale the other toxic compounds of traditional 
smoke (3). Besides, e-cig has been also considered as a 
possible method for smoking cessation (4, 5).
But what is the scientific evidence about the e-cig? 
Despite the great number of scientific articles published 
in recent years (from 2009 to 2014), it is still not possible 
to define an “evidence-based risk profile” for the use of 
e-cig. Indeed, all the systematic reviews and meta-analyses 
published to date on this issue did not define practical con-
clusions, but they only suggested recommendations and the 
necessity to study in deep this problem. For these reasons, 
we considered proper to draw up a “state of the art” about 
all the emerged critical points on this topic. Thus, the aim 
of the present review report was to investigate literature 
data about the e-cig, with particular reference to the features 
“toxicological safety”, “effectiveness in overcoming the 
addiction to smoking the traditional cigarette”, “regulatory 
issues” and “necessary research agenda”.
Interventions for tobacco smoking cessation: why?
Scientific evidences on adverse effects associated to 
smoking versus the high number of smokers
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Tobacco smoking is a well-known risk factor for hu-
man health, and it is associated with a great and increasing 
number of carcinogenic and non-carcinogenic effects (6). 
Indeed, the carcinogenicity of tobacco smoking was already 
evidenced many years ago, with the first scientific evidence 
of the association between cigarette smoking and lung cancer 
published in 1950 (7). These results represented the rationale 
of one of the most important research on the adverse effects 
determined from cigarette smoking: the British Doctors’ 
Study, an epidemiological study designed by Richard Doll 
and Austin Bradford Hill, conducted from 1951 to 2001 
on a very large cohort of British doctors (more than forty 
thousand subjects) that produced many of the current know-
ledge about the risks posed by smoking (8). A great number 
of studies have been performed on adverse effects derived 
from tobacco smoking, both for active and passive smokers 
and, over time, an increasing number of adverse effects and 
diseases have been linked to tobacco smoke (6).
Despite these strong scientific evidences, data relating to 
the adverse effects caused by smoking showed that this habit 
is still one of the most significant problems for public health 
worldwide. The World Health Organization (WHO) estima-
tes that tobacco smoke is currently responsible for the death 
of approximately five million people globally each year, and 
many of these deaths occur prematurely. Moreover, future 
predictions are not encouraging: in the next two decades it 
is expected that the number of deaths caused by smoking 
will be greater than eight million (9). These figures do not 
surprise, considering that there are more than one billion 
smokers worldwide, and that about 10 million cigarettes 
are purchased every minute, with an equivalent of 15 billion 
cigarettes sold every day (10).
As regard to Italian smokers, data show that even in our 
country the smoking habit results in a significant problem: 
the National Institute of Health estimated that, in 2013, the 
prevalence of smoking in the Italian population was equal 
to 20.6%, with a percentage of males and females equal to 
26.2 and 15.3%, respectively (11).
Given the adverse effects on human health caused by 
smoking and the high number of smokers, smoking cessation 
represents a global priority action for public health.
Smoking cessation: smoking habits versus nicotine addiction
“Giving up smoking is the easiest thing in the world. I 
know because I’ve done it thousands of times”. The apho-
rism of Mark Twain can make you smile, but it represents 
a sad reality for smokers. Certainly smoking cessation is 
very difficult for smokers, especially due to physical and 
psychological addiction determined by tobacco products.
The current use of the term “smoking habits” should be 
recognized as improper in light of the fact that cigarette smo-
king and other forms of tobacco use are actually recognized 
as a behavior determined by nicotine addiction. Tobacco 
smoking, indeed, is a real illness, included in the list of men-
tal and behavioural disorders due to psychoactive substance 
use in the 10th revision of the International Classification 
of Diseases ICD-X (12). Nicotine is a component of the 
tobacco products, it is vaporized together with the burning 
of tobacco, and it reaches the lungs through the aspiration 
of the smoke. After about 10-15 seconds from the aspiration 
of smoke, nicotine enters the bloodstream and reaches the 
central nervous system, where it can interact with nicotinic 
cholinergic receptors. This interaction results in the release 
of several neurotransmitters, which produce the typical 
“rewarding” effects such as pleasure, excitement, relaxation, 
reduction of anxiety, etc. Thus, prolonged abstinence from 
nicotine and from all the effects of its intake is a major cause 
of failure of the attempt to quit smoking (3). In addition, 
together with physical abstinence from nicotine, smoking 
cessation involves the loss of the daily gesture of a smoker, 
which is also what justifies the definition of “smoking ha-
bits”. This loss results in an additional factor for the failure 
of smoking cessation. For these reasons, drug therapies or 
nicotine replacement therapy associated with psychological 
support resulted the best interventions to help smokers who 
want to quit smoking (13-16).
Electronic cigarettes: history and epidemiological 
profile
Electronic cigarette was ideated by the Chinese phar-
macist Hon Lik in 2000, with the intention of making the 
first cigarette containing nicotine but no tar. Later, in 2003, 
an ultrasound device that nebulized nicotine dissolved in a 
solution of propylene glycol was produced in China and, in 
2006, this product was exported all over the world with a 
very remarkable success (17). The popularity of the e-cig in 
the smokers community has grown exponentially worldwide, 
becoming the leader product between the various alternatives 
to cigarette smoking (nicotine replacement therapy, other 
therapeutic approaches, etc). Even, in the Korean market, 
e-cig was introduced as a “healthy” alternative to cigarettes, 
and it was publicized as an effective device for smoking ces-
sation (18). The success of this device is also highlighted by 
the great number of new commercial points that were opened 
worldwide with the unique purpose of selling e-cig.
A systematic review on awareness, use, reactions and 
beliefs about e-cig evidenced that the awareness and the use 
e-cig increased, respectively, from 16% to 58% and from 1% 
to 6% in very few years (2009-2011), with some differences 
according to studied countries (19).
In the United States, for example, the prevalence of 
adult vapers (user of e-cig) has doubled from 2010 to 2011 
(2.1 - 3.3 and 6.2%, respectively) (20-23).
Likewise, the number of vapers has been gradually 
increased in Europe: a recent Eurobarometer survey indi-
cates that 7% of Europeans tried e-cig (almost 30 million 
people) (24).
The phenomenon shows a similar trend in Italy: more 
than 45 million Italians know e-cig, 3.5 million tried it, and 
more than 600,000 subjects regularly used it in 2013 (25). 
However, after about six months (from the end of 2013 to 
the half of 2014), Italian situation about e-cig and vapers 
was reversed. A survey conducted by the National Institute 
of Health evidenced a decrease of the e-cig users from 4.2% 
to 1.6% adults (26), and most of the commercial points were 
closed. This phenomenon is very recent and, consequently, 
its explanation is not certain. The decrease in the use of 
e-cig is probably related to different factors, such as the 
uncertainty about its efficacy and safety, the new regulation 
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on e-cig, and the recommendations of caution in their use 
expressed by leading public health agencies (National Insti-
tute of Health, WHO, etc.). These topics will be discussed 
individually in the following paragraphs.
Electronic cigarettes: evidences on its effectiveness for 
smoking cessation
A very recent review on the effectiveness of e-cig as 
a method for smoking cessation can help to understand 
the actual scientific evidence about this issue. The review 
evaluated 6 clinical studies and the most significant results 
were that e-cigarettes significantly reduced the need of 
smoking, the number of cigarettes smoked every day, and 
the concentrations of exhaled carbon monoxide levels. 
Nevertheless, long-term cessation was not sustained at 6 
months (27). Another recent systematic review on the same 
issue reported very similar results, highlighting that e-cig 
can help to decrease the number of cigarettes smoked and 
to reduce the withdrawal symptoms (28).
On the other hand, the results of further studies eviden-
ced that:
– e-cig is not discouraging the use of conventional cigaret-
tes among youths, but it seems to contribute to nicotine 
addiction (29-31);
– about 10% of e-cig vapers are also stable smokers of 
traditional cigarettes and present difficulty in achieving 
smoking cessation (32);
– e-cig is used by smokers not only as a method to reduce or 
quit smoking, but also to smoke in an indoor environment 
avoiding the smoking bans for enclosed environment, such 
as cinemas, restaurants, public transports, etc. (4, 5);
– smokers, especially young, do not seem motivated to 
quit smoking conventional cigarettes, but rather they are 
attracted by the novelty (33). It is well-known that young 
people has always been a segment of the population most 
involved in the use of new products and abuse of drug 
substances (34);
– even if e-cig is more commonly used by smokers, it is 
not limited to them; several researches estimated that the 
prevalence of experimentation of e-cig in never-smokers 
population ranged from 0.1 to 3.8% (35);
– e-cig is often perceived as a safer smoking alternative by 
smokers, including pregnant women; thus, since nicotine 
can determine fetal adverse effects, pregnant mothers 
that smoke e-cig could cause even greater fetal damage 
because women can use these devices more freely respect 
to traditional cigarettes during pregnancy (36, 37).
The efficacy of e-cig was compared to other nicotine repla-
cement therapy; in particular, e-cig contains 16 mg of nicotine, 
used ad libitum, was compared with the patch containing 21 
mg of nicotine, (one day) in a large sample of smokers. The 
results evidenced that, after six months, 7.3% of the subjects 
who used the e-cig and 5.8% of the individuals treated with 
the patch were completely abstinent. In addition, 57% of e-cig 
group and 41% of the patch group reduced by at least half the 
consumption of tobacco cigarettes. Consequently, according 
to this study, e-cig may be considered slightly more effective 
than patch in smoking cessation (38).
Another recent study investigated the reasons associated 
with the use of e-cig for cessation help versus the use of 
other proven cessation aids. E-cig resulted a valid alternative 
“smoking” experience for smokers that wish to quit smoking 
not because of concerns about health, but for the immediate 
and undesirable consequences of tobacco smoking (smell, 
ash, litter, etc). Consequently, e-cig may be efficacy to reduce 
tobacco exposure among smokers who do not want to quit 
smoking for intrinsic motivation (39).
Several limitations emerged from these studies: small 
or unrepresentative population samples, a high number of 
losses during follow-up, the short duration of the follow-up. 
Researchers should make efforts to overcome these limita-
tions, in order to obtain more robust scientific evidences on 
effectiveness of e-cig to quit smoking.
Electronic cigarettes: evidences on toxicological safety
In the last years studies on the toxicological safety of e-
cig are increased, as demonstrated by the growing number of 
scientific papers published on this issue. A simple literature 
search on PubMed using the key words “e-cigarette” and 
“safety” involves the finding of 88 scientific articles, the first 
published in 2009 and more than half published in 2014.
The majority of these papers are critical or systematic 
reviews regarding toxicological data presented in specific 
technical reports produced for single e-cigs (40-44). Howe-
ver, given the wide range of devices, cartridges and flowe-
ring, it is difficult to draw general conclusions applicable to 
the entire range of products. Besides, the production and the 
import/export of the products are not well controlled and, 
consequently, it is difficult to regulate these products. In 
addition, at today there are no standardized methodologies 
for generating and testing the aerosol generated by e-cig 
as those used for traditional cigarettes. Moreover, even in 
the case of a toxicological evaluation of the compounds 
content in e-cig, it is difficult to provide a valid human 
exposure assessment and a human risk evaluation because 
the mode of use of e-cig is very individual. Also, consi-
dering the recent introduction of e-cig, long-term studies 
to evaluate the effects of e-cig after chronic exposure are 
not still performed. Finally, notice that many studies are 
financed by e-cig producers and, thus, possible conflict of 
interest should be considered.
Traditionally, the attention of the researches evaluating 
the safety of e-cigs has been focused on the possible risks 
on human health derived from nicotine, flavours and propy-
lene glycol (the major ingredient of e-cig). However, very 
recently some authors demonstrated possible additional risks 
related to the release of a not negligible amount of some 
heavy metals from the devices itself (45), and the presence 
of diacetyl and acetyl propionyl in the sweet-flavoured e-cigs 
liquids. These compounds are approved for food use but, 
at the same time, are associated with respiratory diseases 
when inhaled (46).
Some answers about the safety of e-cigs were given by 
experts in the field (40-44): they confirmed the lower toxi-
city of e-cigs when compared to the conventional tobacco 
products. However, all authors agree that available data are 
too limited to draw strong conclusions.
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Electronic cigarettes: evidences on other possible 
harms
In addition to the toxicological harms linked to the smo-
king of e-cig, other additional risks for human health were 
recently highlighted.
The liquid mixture used for refilling the cartridge may 
pose several risks of exposure. The National Poison Control 
Centre in Milan (Italy), for example, handled 172 cases of 
exposures to liquid derived from different exposure scena-
rios. Some cases occurred in children < 5 years old, due 
to unintentional ingestion or dermal/mucosal contact as a 
result of uncontrolled access to mixtures. Other cases were 
related to the exposure (by ingestion, inhalation, or dermal/
mucosal contact) to liquid accidentally leaked during the 
use of e-cig. Further accidental exposures derived from the 
misapplication of the liquid solution for e-cig instead of 
drugs to be administered in drops. Few cases, finally, were 
related to intentional exposures for suicidal purpose or to 
the abuse of e-cig (47).
Another relevant issue related to e-cig is represented by 
its use in indoor environments, that determines a decrease 
of air quality due to the emission of particulate matter (PM) 
and other pollutants and passive smoking via inhalation of 
non-vapers (48). Pellegrino et al. (49) found that the smoke 
of e-cig increases ultrafine PM of the indoor environments, 
slightly exceeding WHO air quality guidelines (50), even 
if these levels resulted 15 times lower than emissions of 
traditional cigarettes (51). Besides, e-cig smoking relea-
ses several toxicants such as nicotine and, in some cases, 
tobacco-specific nitrosamines and other compounds that 
may persist for many days on surfaces (52-54).
Thus, passive smoking of e-cig emissions consists both 
of an exposure concurrent with e-cig use and an exposure 
that occurs after e-cig use. This phenomenon is well known 
for conventional cigarettes, and is called Environmental 
Tobacco Smoke (ETS). ETS is a mixture of chemical com-
pounds released from the smouldering of tobacco products. 
Notice that ETS is an important threat for the health of the 
non-smokers (6, 55), especially for children. In particular, 
early exposure to ETS (first years of life) may determine the 
development of diseases in adult age, such as leukaemia, 
other cancers, chronic respiratory and cardiovascular disea-
ses etc. (56-58). ETS is a combination of second- and third-
hand smoke. Secondhand smoke (SHS) is the inhalation of 
chemicals due to the smoke exhaled by a smoker together 
with the smoke from a burning cigarette, while third-hand 
smoke (THS) is the combination of tobacco smoke pollutants 
that persist, long after the extinguish of the cigarette, on 
clothing and hair of smokers and on surfaces, furnishings, 
and dust of indoor environments. Thus, SHS exposure is the 
unintentional inhalation of smoke that occurs close to peo-
ple smoking, while THS exposure consists of unintentional 
intake of smoke that occurs in indoor environments in the 
absence of concurrent smoking (59, 60).
In the same way, the use of e-cig in indoor environments 
determines a type of passive smoking that we propose to call 
Environmental Electronic Smoke (EES). EES is the sum of 
electronic SHS (e-SHS) and electronic THS (e-THS). This 
issue represents a critical research agenda and should be 
studied in deep.
Electronic cigarettes: recommendations and 
regulations
When e-cig was introduced in trade, it was not regula-
ted. Then, the exponential increase in their use asked for an 
official opinion of public health experts about its efficacy 
for smoking cessation and its safety. For this reason, in Sep-
tember 2008, WHO declared that e-cig can not be considered 
as a method to quit smoking, due to inadequate researches 
demonstrating its effectiveness. Besides, WHO suggested 
caution in its use, until the possible risks related to some of 
its ingredients and constituents is better evaluated (61, 62). 
Successively, in 2014, WHO expressed a new opinion on 
e-cig, calling for local regulations that inhibit the promotion 
of e-cigs and the use of unproved health claims, and ban 
their use indoors (63, 64).
The recommendations of WHO on e-cig came under 
pressure from both pro-e-cig and contra-e-cig supporters. 
In contrast to the conventional tobacco debate with the 
agreement of the entire scientific community, the actual 
debate on e-cig finds public health scientists on both sides, 
and both expressed their opinion to WHO: On 29 May 2014, 
53 scientists signed a ‘‘pro’’ letter sent to WHO, three week 
later, 129 researchers signed a ‘‘contra’’ letter sent in reaction 
to the first one (65).
The “pro” letter referred to e-cig as “an innovation with 
potential to save many millions of lives”. The signatories of 
this letter highlighted that after one decade of rapid raise of 
e-cig and an increasing number of researches, there is still a 
lack of evidence of any harms associated with their use; con-
sequently, if any risk related to the use of e-cig is ever found, 
it should not be as common as lung cancer related to tobacco 
smoking. Besides, even the strongest antagonists to e-cig do 
not predict that the risk in the use of smokeless tobacco or 
e-cig by smokers may be comparable to the hazards related 
to traditional cigarettes. In addition the “pro” e-cig scientists 
considered the risk of the use of e-cig by young non-smokers 
as a theoretically possible threat, but not yet been supported 
by any study (66). The reply “contra” letter highlights the 
scientific evidences emerged on the health risks related to 
the nicotine, the vapour and some heavy metals contained 
in e-cig, and the lack of evidence about the effectiveness 
of e-cig as a method for smoking cessation; thus, the use 
of e-cigs must be considered with the proper caution and it 
must be subject to appropriate regulation (67).
At today, regulation about e-cig is still not harmonized. 
The European Commission in 2012, for example, included 
e-cigs in the proposal for a novel Tobacco Product Directive, 
but considering only the products containing more than 2 
mg nicotine per unit or 4 mg nicotine/ml liquid. Then, at the 
end of 2013, the European Parliament amended a proposal 
that dismissed any upper limit with regard to the nicotine 
contents in these products, with the except of products con-
taining more than 30 mg nicotine/ml liquid. Afterward, on 
February 2014, the negotiations between European Council, 
Commission, and Parliament, led to the approval of a pro-
posal that set at 20 mg/ml, or 200 mg per 10 ml refill bottle 
the upper limit for nicotine content (68).
As regard to the Italian legislation on e-cig, regulations 
are changed widely in few months. In June 2013, a specific 
law banned the use of e-cig from public places, but in Sep-
36
                                      C. Protano et al.
tember 2013 a new decree permitted the use of e-cig both 
indoors and outdoors, excluding schools. After 3 months, 
an additional act introduced the ban for e-cig in the indoor 
environments together with a maxi-taxation for e-cig sale 
(an increase of 200%), that was withdrawn very soon after 
its approval (69).
Conclusions
Considering all the arguments discussed in the present 
report, we can highlight some bullet points:
1. there is a strong need for harmonizing the methods for 
assessing the risks related to the use of e-cig, both for 
smokers and those exposed to EES;
2. the human health risk assessment process and the 
evaluation of the safety both of e-cig device and liquid 
solutions must be performed before the introduction in 
trade of these products;
3. there is a need for the evaluation of the effectiveness of 
these devices as methods for smoking cessation;
4. the sale of e-cigs, especially those containing nicotine, 
must be treated as the other devices containing potential 
toxic compounds or nicotine replacement therapies; a 
valid possibility is the pharmacy. In fact pharmacists 
have the right competence and contact with patients/
customers for guide their choices on e-cigs, and follow 
them over time;
5. there is a need for clear and harmonized regulations on 
e-cigs both for protecting vapers and people exposed to 
EES;
6. advertising and information on e-cig, sometimes positive 
and sometimes negative, has created much confusion in 
general population; there is a need for an appropriate 
risk communication process, managed by official public 
health operators, to avoid misunderstandings on this new 
health issue.
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